High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era
- 1 March 2016
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 42, 1-6
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab eraBlood, 2014
- Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOPJournal of Clinical Oncology, 2011
- Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010
- Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic IndexBlood, 2007
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvementEuropean Journal of Haematology, 2006
- New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.Journal of Clinical Oncology, 1998
- A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's LymphomaBlood, 1997
- Bone Marrow Involvement in Large-cell Lymphoma:Prognostic Implications of Discordant DiseaseAmerican Journal of Clinical Pathology, 1994
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993